{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:47:43Z","timestamp":1792759663510,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10637-022-01308-5","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T10:03:37Z","timestamp":1667556217000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors"],"prefix":"10.1007","volume":"41","author":[{"given":"Shubham","family":"Pant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Dragovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madappa","family":"Kundranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eskouhie","family":"Tchaparian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchih C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"issue":"6","key":"1308_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1185\/030079906X104849","volume":"22","author":"Rainsford KD, Members of the Consensus Report Group on Nimesulide","year":"2006","unstructured":"Rainsford KD, Members of the Consensus Report Group on Nimesulide (2006) Nimesulide \u2013 a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 22(6):1161\u20131170","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1308_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2004-5-9-241","volume":"5","author":"N Chandrasekharan","year":"2004","unstructured":"Chandrasekharan N, Simmons DL (2004) The cyclooxygenases. Genome Biol 5(9):1\u20137","journal-title":"Genome Biol"},{"issue":"sup442","key":"1308_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/00016488709102833","volume":"104","author":"TC Laurent","year":"1987","unstructured":"Laurent TC (1987) Biochemistry of hyaluronan. Acta Otolaryngol 104(sup442):7\u201324","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"1308_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu B, Qu L, Yan S (2015) Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 15(1):1\u20136","journal-title":"Cancer Cell Int"},{"issue":"5","key":"1308_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"Oshima M et al (1996) Suppression of intestinal polyposis in Apc\u0394716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803\u2013809","journal-title":"Cell"},{"issue":"9","key":"1308_CR6","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI119400","volume":"99","author":"H Sheng","year":"1997","unstructured":"Sheng H et al (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Investig 99(9):2254\u20132259","journal-title":"J Clin Investig"},{"issue":"3","key":"1308_CR7","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.3748\/wjg.v8.i3.483","volume":"8","author":"G Tian","year":"2002","unstructured":"Tian G et al (2002) Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells. World J Gastroenterol 8(3):4838","journal-title":"World J Gastroenterol"},{"key":"1308_CR8","doi-asserted-by":"crossref","unstructured":"Jian YS et al (2017) Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Int J Nanomedicine 27(12):2315\u20132333","DOI":"10.2147\/IJN.S120847"},{"issue":"6","key":"1308_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S et al (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162(6):1257\u20131270","journal-title":"Cell"},{"issue":"1","key":"1308_CR10","first-page":"692","volume":"8","author":"LH Zhao","year":"2015","unstructured":"Zhao LH et al (2015) CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol 8(1):692\u2013701","journal-title":"Int J Clin Exp Pathol"},{"key":"1308_CR11","volume-title":"CA102N, a conjugate of hyaluronic acid (HA) and Nimuselide derivative (H-Nim) interferes with PI3K\/Akt\/mTOR signaling pathway in colorectal cancer (CRC) cells and inhibits tumor growth in vivo","author":"EH Tchaparian","year":"2017","unstructured":"Tchaparian EH, Lin L (2017) CA102N, a conjugate of hyaluronic acid (HA) and Nimuselide derivative (H-Nim) interferes with PI3K\/Akt\/mTOR signaling pathway in colorectal\u00a0 cancer (CRC) cells and inhibits tumor growth in vivo. AACR"},{"issue":"2","key":"1308_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1245\/s10434-010-1268-9","volume":"18","author":"YJ Zhang","year":"2011","unstructured":"Zhang YJ et al (2011) mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol 18(2):580\u2013588","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1308_CR13","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00432-020-03315-6","volume":"146","author":"T Walter","year":"2020","unstructured":"Walter T et al (2020) Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol 146(10):2575\u20132587","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1308_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumors: revised\u00a0 RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"1","key":"1308_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchromb.2008.06.042","volume":"871","author":"JR Neale","year":"2008","unstructured":"Neale JR, Dean BJ (2008) Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 871(1):72\u201377","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"45","key":"1308_CR16","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.3748\/wjg.v16.i45.5651","volume":"16","author":"F Bessone","year":"2010","unstructured":"Bessone F (2010) Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 16(45):5651","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1308_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209264","volume":"14","author":"J Kwon","year":"2019","unstructured":"Kwon J et al (2019) Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis. PLoS ONE 14(1):e0209264","journal-title":"PLoS ONE"},{"issue":"1","key":"1308_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/bcp.12938","volume":"82","author":"M Donati","year":"2016","unstructured":"Donati M et al (2016) Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case\u2013control study in Italy. Br J Clin Pharmacol 82(1):238\u2013248","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"1308_CR19","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01308-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T13:08:12Z","timestamp":1679404092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01308-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"26 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Colorado Hospital Anschutz Cancer Pavilion, Banner MD Anderson Cancer Center, and University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Financial interests: Eskouhie Tchaparian and Y.C. Chen are employees of Holy Stone Healthcare Co., Ltd., and may own stock\/stock options in the company. The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}